CXM Financial Facts
Research and development: 108.67KNet loss: -1.19M
See Full Income Statement
Total liabilities: 3.41M
Total current assets: 38.05K
See Full Balance Sheet
Cardium Therapeutics, Inc. (CXM) Earnings
|
Expand Research on CXM
| Next EPS Date | N/A | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +30.3% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +5.9% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
3/11/26  |
Q426 | N/A | $0.09 | N/A | N/A | $215.51M | = | N/A | N/A | ||
| 12/3/25 | Q326 | $0.12 | $0.09 | +$0.03 | $219.1M | $209.56M | = |  | | Details | |
| 9/3/25 |
Q226 | N/A | $0.10 | N/A | N/A | $205.4M | = | N/A | N/A | ||
| 6/4/25 | Q126 | $0.12 | $0.10 | +$0.02 | $205.5M | $201.88M | = | | | Details | |
| 3/12/25 | Q425 | $0.10 | $0.07 | +$0.03 | $202.5M | $200.52M | = | | | Details | |
| 12/4/24 | Q325 | $0.10 | $0.08 | +$0.02 | $200.7M | $196.48M | = | | | Details | |
| 9/4/24 | Q225 | $0.06 | $0.07 | -$0.01 | $197.2M | $194.51M | = | | | Details | |
| 6/5/24 | Q125 | $0.09 | $0.07 | +$0.02 | $196M | $194.37M | = | | | Details |
